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Abstract Eukaryotic initiation factor 4E-binding protein 1
(4E-BP1) represses translation initiation by binding to eukary-
otic initiation factor 4E (eIF4E). 4E-BP1 also binds to the
eIF4E homologous protein (4EHP). We show that eIF4E-bind-
ing mutants of 4E-BP1 (Y54A and L59A) fail to form hetero-
dimeric complexes with wild-type 4EHP. In addition, the W95A
mutant of 4EHP, similar to a homologous mutation in eIF4E,
inhibits its binding to wild-type 4E-BP1. Interestingly, 4EHP
over-expression instigates a negative feedback loop that inhibits
upstream signaling to 4E-BP1 and ribosomal protein S6 kinase
1 (S6K1) whereas the 4E-BP1-binding-de¢cient mutant of
4EHP(W95A) was unable to trigger this feedback loop. Thus,
the interaction of 4EHP with 4E-BP1 is necessary for this
observed impaired signaling to 4E-BP1 and S6K1.
0 2004 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
Protein synthesis requires three stages of mRNA translation
termed initiation, elongation, and termination. Control of
protein synthesis is largely governed by a cohort of eukaryotic
initiation factors (eIFs) that mediate speci¢c steps in the ini-
tiation process (for review see [1]). A rate-limiting step in
translation initiation involves the formation of the eIF4F
complex that recruits ribosomal subunits to the mRNA, a
process known as cap-dependent translation. The cap-binding
pocket of eIF4E interacts with the cap moiety (7-methylgua-
nosine triphosphate (m7GTP)) positioned at the extreme 5P
end of the mRNA. eIF4E interacts with eIF4G that in turn
binds to eIF4A, a bi-directional RNA helicase, to form the
eIF4F complex. eIF4G is a large sca¡old protein that recruits
many other factors to the 5P cap structure, including poly(A)-
binding protein, eIF3, and the eIF4E kinases, Mnk1 and
Mnk2 (see review [1]). Formation of the eIF4F complex,
and thus cap-dependent translation, is antagonized by
eIF4E-binding proteins (4E-BPs), during conditions of low
mitogenic and nutrition su⁄ciency.
The eIF4E-binding motif of 4E-BP1 interacts with a region
of eIF4E, which also binds to eIF4G [2]. Therefore, interac-
tion of 4E-BP1 to eIF4E blocks eIF4F complex formation by
preventing the binding of eIF4G to eIF4E. Phosphorylation
of 4E-BP1 antagonizes its binding to eIF4E. During condi-
tions of mitogenic and nutrient su⁄ciency, 4E-BP1 becomes
phosphorylated and dissociates from eIF4E. This allows
eIF4E to participate in the formation of the eIF4F complex.
4E-BP1 phosphorylation occurs in a hierarchical manner at
seven characterized (Ser/Thr)Pro-directed sites (Thr37, -46,
and -70 and Ser65 -82, -101, and -112, numbering according
to the human sequence) [3,4]. Phosphorylation of sites that lie
proximal to the eIF4E-binding domain of 4E-BP1, Thr46 and
Ser65, is considered to be critical for disrupting the binding of
4E-BP1 to eIF4E.
Given that the regulation of 4E-BP1 is complex, it is likely
that 4E-BP1 interacts with many signaling components that
are presently uncharacterized. To identify potential 4E-BP1-
interacting proteins we carried out a yeast two-hybrid screen
using 4E-BP1 as bait. We discovered that eIF4E homologous
protein (4EHP) interacted with the eIF4E-binding motif of
4E-BP1. In this study, we further characterize this interaction
and discover that high levels of 4EHP protein can trigger a
negative feedback loop in cells that inhibits upstream signal-
ing towards both 4E-BP1 and ribosomal protein S6 kinase 1
(S6K1).
2. Materials and methods
2.1. Plasmids
Mouse 4E-BP1 (a gift from J. Lawrence, University of Virginia
School of Medicine, Virginia) was subcloned into pGBDU-C3 (pro-
vided by S.M. Hollenberg, Vollum Institute, Oregon) for use in the
yeast two-hybrid screen. pACTAG2 expressing human HA-tagged
4E-BP1 was provided by N. Sonenberg (McGill University, Canada).
Human 4EHP (ATCC number 7387103) and eIF4E (provided by N.
Sonenberg) were subcloned into pRK7 so that they were expressed
with an N-terminal Flag epitope (MDYDDDDK). S6K1 and F5A-
vct S6K1 expression vectors were generated as previously described
[5]. Point mutants were generated by site-directed mutagenesis (Quik-
Change; Stratagene).
2.2. Analysis of protein phosphorylation and association of translation
factors
Human embryonic kidney 293E (HEK293E) cells were cultured (at
37‡C within 5% CO2) and maintained in Dulbecco’s modi¢ed Eagle’s
medium supplemented with 10% fetal bovine serum. CaPo4 transfec-
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tions were performed as previously described [5]. After treatment, cells
were harvested and Western blot analysis was carried out as before
[6]. Anti-Flag antibodies (M2) were purchased (Eastman Kodak,
Newhaven, CT, USA). Anti-HA antibody was a kindly provided by
M. Chou (University of Pennsylvania) and anti-4E-BP1 phospho-spe-
ci¢c antibodies were bought from Cell Signaling Technology. eIF4E
and 4EHP was puri¢ed by using a⁄nity chromatography on m7GTP-
Sepharose as previously described [7]. Cross-linking reaction was car-
ried out with DSP (Pierce) as previously described [8].
2.3. Immunoprecipitation and immune complex kinase assays
For immunoprecipitation studies of HA-tagged S6K1, cell extracts
were immunoprecipitated with an anti-HA antibody bound to protein
A-Sepharose (Pharmacia) for 3 h. Immunoprecipitates were washed as
previously described [9]. Kinase activity of S6K1 was then determined
using recombinant glutathione S-transferase (GST)-S6 as a substrate,
as previously described [9].
3. Results
3.1. 4EHP interacts with the eIF4E-binding domain of 4E-BP1
Yeast two-hybrid analysis was carried out to identify novel
interactors of 4E-BP1. A PJ69-4A yeast strain was ¢rst trans-
formed with pGBDU-C3, which contained full-length mouse
4E-BP1 fused to the Gal4 DNA-binding domain. The PJ69-
4A yeast strain containing 4E-BP1 in pGBDU-C3 was then
transformed with a two-hybrid cDNA library created from
day 9.5 and 10.5 mouse embryos [10]. Approximately 2U107
transformants were screened, which is 100 times the complex-
ity of the library after ampli¢cation. Fifty-one His+ colonies
were obtained from the primary screen, of which 29 were
further selected with greater stringency in the absence of ad-
enine. The library plasmids were then recovered and se-
quenced. Nine of the isolated plasmids contained sequences
encoding all or part of 4EHP, which is highly homologous to
eIF4E (30% identical and 60% similar, see Fig. 1A). eIF4E, a
well characterized translation initiation factor that interacts
with 4E-BP1, was also recovered from the screen (see review
[1]).
To examine whether 4EHP bound to 4E-BP1 in a manner
analogous to that of eIF4E, 4E-BP1 mutants with single
(Y54A and L59A) and double (Y54A/L59A) point mutations
within the eIF4E-binding domain of 4E-BP1 were generated.
Both single and double point mutants of 4E-BP1 abolished
4EHP’s interaction with 4E-BP1, indicating that 4EHP binds
to the eIF4E-binding domain of 4E-BP1 (Fig. 1B). Binding of
4EHP to 4E-BP1 is likely weaker than that of eIF4E to 4E-
BP1 as eIF4E was still able to interact with the single point
mutants of 4E-BP1 (Y54A and L59A) while 4EHP was not.
Fig. 1. 4E-BP1 interacts with 4EHP through the eIF4E-binding motif. A: Amino acid alignment of human 4EHP and eIF4E. Conserved Trp
residues are labeled accordingly. The Ser209 phosphorylation site within eIF4E is also marked. B: PJ69-4A yeast transformed with DNA-bind-
ing fusion proteins (4E-BP1 wild-type (Wt), and 4E-BP1 (Y54A, L59A, and Y54A/L59A)) and activation domain fusion proteins (4EHP,
eIF4E, and 4EHP(W95A)) were grown on media lacking uracil (3URA) and leucine (3LEU). Positive interaction was determined by growth
on minus histidine plates (3HIS).
FEBS 28266 8-4-04
A.R. Tee et al./FEBS Letters 564 (2004) 58^62 59
It is known that Trp73 within eIF4E is required for eIF4E’s
interaction with 4E-BP1 [11,12]. Based on the sequence align-
ment (Trp95 of 4EHP aligns with Trp73 of eIF4E, Fig. 1A),
we generated a mutant of 4EHP where Trp95 was substituted
to alanine. Given that Trp73 lies on the dorsal surface of
eIF4E [12], it is likely that the Trp95 residue of 4EHP is
also exposed and interacts with 4E-BP1. Indeed, the 4EHP-
(W95A) mutant was unable to associate with 4E-BP1 (Fig.
1B), revealing that a homologous region within both eIF4E
and 4EHP is required for 4E-BP1 binding.
3.2. The 4EHP(W95A) but not the 4EHP(W135A) mutant
associates with the m7GTP cap moiety
Previously, 4EHP was shown to interact with the m7GTP
cap moiety that is located at the extreme 5P end of most
mammalian mRNA transcripts [13]. These studies also re-
vealed that a mutant of 4EHP with Trp135 substituted to
an alanine prevented cap binding [13]. Trp135 of 4EHP aligns
with Trp113 of eIF4E (see Fig. 1A), a residue that is required
for the binding of eIF4E to the m7GTP cap structure [13].
Puri¢cation of wild-type and mutant forms of 4EHP on
m7GTP-Sepharose was compared to that of eIF4E (Fig. 2).
Both eIF4E and 4EHP associated with the m7GTP cap struc-
ture. eIF4E, however, was more abundantly puri¢ed than
4EHP using this technique even though approximately equal
amounts of starting material were used. The 4EHP(W95A)
mutant protein, which was unable to interact with 4E-BP1
(Fig. 1B), was also puri¢ed using m7GTP a⁄nity chromatog-
raphy while the 4EHP(W135A) mutant was not (Fig. 2).
Therefore, mutation of Trp95 to alanine is su⁄cient to block
the interaction of 4E-BP1 with 4EHP (Fig. 1B) but does not
prevent the binding of 4EHP with the m7GTP cap structure
(Fig. 2).
3.3. 4EHP over-expression impairs insulin-stimulated 4E-BP1
phosphorylation, which requires 4E-BP1’s interaction with
4EHP
Previously it was shown that 4EHP did not co-purify with
4E-BP1 using standard immunoprecipitation methods [13].
Similarly, we were unable to co-purify 4E-BP1 with 4EHP
Fig. 2. 4EHP(W95A) still retains m7GTP a⁄nity. Flag-tagged
eIF4E, 4EHP, 4EHP(W95A) and 4EHP(W115A) were over-ex-
pressed in HEK293E cells and puri¢ed on m7GTP-Sepharose beads
from cell lysates (bottom panel). The amount of protein expressed is
shown in the upper panel (‘load’).
Fig. 3. 4EHP over-expression impairs insulin-stimulated 4E-BP1 phosphorylation and requires 4E-BP1 interaction with 4EHP. A: HEK293E
cells co-expressing Flag-tagged 4EHP and 4EHP(W95A) with either HA-tagged wild-type 4E-BP1 or 4E-BP1(Y54A/L59A) were serum-starved.
These cells were pre-treated with 20 nM rapamycin (rap) for 30 min prior to being stimulated with insulin (100 nM) for 30 min as indicated.
The amount of 4EHP expressed was determined with the anti-Flag antibody. Phosphorylation of ectopically expressed 4E-BP1 was determined
with anti-HA and phospho-speci¢c 4E-BP1 antibodies that recognize pThr37 and/or pThr46, pSer65, or pThr70, as indicated. The K-, L-, and
Q-species of 4E-BP1 are indicated. B: Cells treated as in A were lysed in the presence of DSP cross-linker as described in Section 2. Flag-tagged
4EHP was immunoprecipitated with the anti-Flag antibody and the amount of HA-tagged 4E-BP1 associated with 4EHP was determined.
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using routine immunoprecipitation procedures (data not
shown). Interestingly, during these preliminary experiments
we observed that over-expression of 4EHP impaired 4E-BP1
phosphorylation (data not shown).
To extend this ¢nding further, N-terminal Flag-tagged wild-
type 4EHP or 4EHP(W95A) were over-expressed in serum-
starved HEK293E cells and the phosphorylation of co-ex-
pressed N-terminal HA-tagged wild-type 4E-BP1 or 4E-BP1-
(Y54A/L59A) was investigated after the cells were stimulated
with insulin (Fig. 3A). Three di¡erent phosphorylated species
of 4E-BP1 resolve on sodium dodecyl sulfate^polyacrylamide
gel electrophoresis with Q- and K-isoforms being the most and
least phosphorylated species, respectively. Over-expression of
wild-type 4EHP blocked the basal and the insulin-stimulated
phosphorylation of wild-type 4E-BP1 as observed by a higher
proportion of 4E-BP1 that resolved as the least phosphorylat-
ed K-species, when compared to the pRK7 vector only con-
trol. Over-expression of wild-type 4EHP also repressed the
phosphorylation of 4E-BP1 at Thr37 and/or Thr46, Ser65,
and Thr70. Interestingly, wild-type 4EHP did not inhibit the
phosphorylation of 4E-BP1(Y54A/L59A), a mutant of 4E-
BP1 that cannot interact with either eIF4E or 4EHP (see
Fig. 1B). Similarly, over-expression of 4EHP- (W95A), a mu-
tant of 4EHP that cannot associate with 4E-BP1 (see Fig. 1B),
did not impair wild-type 4E-BP1 phosphorylation. These data
indicate that 4EHP must interact with 4E-BP1 to impair its
phosphorylation.
The above data imply that 4EHP interacts with 4E-BP1
within cells. To investigate this interaction in more detail,
we prepared cell extracts in the presence of a DSP cross-linker
to maintain the initiation complexes (Fig. 3B). Wild-type 4E-
BP1 associated with wild-type 4EHP while no interaction was
observed when binding mutants of either 4E-BP1 or 4EHP
were used. Insulin stimulation is known to cause the dissoci-
ation of 4E-BP1 from eIF4E as a result of increased 4E-BP1
phosphorylation [3,4]. Insulin did not induce the release of
4E-BP1 from 4EHP (Fig. 3B) and can be explained by the
impaired phosphorylation state of 4E-BP1, when 4EHP is ex-
pressed to high levels (see Fig. 3A).
3.4. High expression of wild-type 4EHP but not the W95A
mutant inhibits S6K1 activation
High levels of eIF4E expression have also been shown to
trigger a negative signaling feedback loop leading to the de-
phosphorylation of 4E-BP1 and S6K1 [14]. Therefore, we
wanted to determine whether 4EHP over-expression could
similarly impair insulin-induced S6K1 activation. Both wild-
type eIF4E and 4EHP over-expression signi¢cantly impaired
insulin-stimulated S6K1 activation (Fig. 4). In contrast, the
mutant of 4EHP that does not interact with 4E-BP1 (4EHP-
(W95A), see Figs. 1B and 3B) did not inhibit insulin-induced
S6K1 activation. These data suggest that 4EHP must form a
complex with 4E-BP1 to instigate this negative feedback loop
that occurs upstream of both 4E-BP1 and S6K1.
3.5. High expression of either eIF4E or 4EHP inhibits 4E-BP1
phosphorylation
Our studies reveal that a negative signaling feedback loop
towards both 4E-BP1 and S6K1 is activated when high levels
of 4EHP protein are present within mammalian cells, which is
similar to that observed when eIF4E is expressed at high
levels. Given that the binding a⁄nity of 4EHP to 4E-BP1
was weaker than that observed for eIF4E to 4E-BP1 (Fig.
1B), we wanted to determine whether eIF4E was more potent
at inducing this negative feedback loop. To do this we ex-
pressed di¡erent amounts of eIF4E and 4EHP protein with
a ¢xed amount of 4E-BP1 in HEK293E cells and monitored
4E-BP1 phosphorylation (Fig. 5). Based on this analysis, we
observed a signi¢cant di¡erence in the ability of over-ex-
pressed eIF4E and 4EHP to initiate the observed feedback
loop. For instance, eIF4E prevented insulin-stimulated 4E-
BP1 phosphorylation at the lowest concentrations used where-
as 4EHP yielded partial inhibition of 4E-BP1 phosphorylation
at the highest amount ectopically expressed in this represen-
tative experiment.
4. Discussion
In this study we show that 4E-BP1 interacts with 4EHP in a
manner similar to that of eIF4E. We also show that 4EHP
interacts with the known eIF4E-binding motif within 4E-BP1
(Figs. 1B and 3B). Furthermore, we demonstrate that Trp95
within 4EHP is a critical residue that mediates this interaction
(Figs. 1B and 3B). Importantly, the 4EHP(W95A) mutant can
be a⁄nity puri¢ed with the m7GTP cap analogue (Fig. 2),
showing that Trp95 residue is involved in 4E-BP1/4EHP com-
plex formation rather than cap binding. Our ¢ndings also
suggest that the binding a⁄nity of 4EHP to 4E-BP1 is weaker
than that of eIF4E with 4E-BP1. For instance, eIF4E still
interacts with 4E-BP1 possessing single amino acid point mu-
tants within the eIF4E-binding motif (either Y54A or L59A),
while 4EHP did not (Fig. 1B). Indeed, routine immunoprecip-
Fig. 4. Over-expression of 4EHP but not 4EHP(W95A) impairs
S6K1 activation. HEK293E cells co-expressing HA-tagged S6K1
with either Flag-tagged eIF4E, 4EHP or 4EHP(W95A) were serum-
starved. The cells were pre-treated with 25 nM rapamycin for 30
min and then stimulated with 100 nM insulin where indicated. Pro-
tein levels of eIF4E, 4EHP and S6K1 were determined. S6K1 activ-
ity assays were carried out as described in Section 2. Incorporation
of 32P label into GST-S6 substrate is shown in the bottom panel.
An autoradiograph of the gel is presented.
Fig. 5. eIF4E is more potent at impairing insulin-stimulated 4E-BP1
phosphorylation than 4EHP. Increasing amounts of either eIF4E or
4EHP were co-expressed with HA-tagged 4E-BP1 in serum-starved
HEK293E that were stimulated with 100 nM insulin for 30 min,
where indicated. The levels of eIF4E and 4EHP protein and the ex-
tent of 4E-BP1 phosphorylation were determined.
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itation methods are su⁄cient to maintain 4E-BP1/eIF4E com-
plexes but not 4E-BP1/4EHP complexes implying that associ-
ation of 4EHP with 4E-BP1 is disrupted upon low salt and
detergent conditions (see [13]).
This work also extends the original studies that showed that
high expression levels of eIF4E turned o¡ translation initia-
tion through impaired signaling to 4E-BP1 and S6K1 [14]. We
show that this mechanism also applies to 4EHP, where a high
level of 4EHP expression triggers this negative feedback loop.
We show that the activation of this feedback mechanism
is directly caused by the formation of either 4E-BP1/4EHP
or 4E-BP1/eIF4E complexes (Figs. 1A and 5). Interestingly,
higher levels of 4EHP expression were required to inhibit 4E-
BP1 phosphorylation, when compared to eIF4E (Fig. 5). This
observation can be explained by the stronger binding a⁄nity
that eIF4E has with 4E-BP1 when compared to 4EHP. So
what is the purpose of this negative feedback loop? It is
known that a high level of eIF4E expression causes transfor-
mation [15]. Therefore, it may be possible that this negative
feedback loop functions as a checkpoint control mechanism
that is utilized to protect cells from an inappropriately high
translation rate when eIF4E or 4EHP are vastly over-ex-
pressed.
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